AU2008100233A4 - Oral anaesthetic gel - Google Patents
Oral anaesthetic gel Download PDFInfo
- Publication number
- AU2008100233A4 AU2008100233A4 AU2008100233A AU2008100233A AU2008100233A4 AU 2008100233 A4 AU2008100233 A4 AU 2008100233A4 AU 2008100233 A AU2008100233 A AU 2008100233A AU 2008100233 A AU2008100233 A AU 2008100233A AU 2008100233 A4 AU2008100233 A4 AU 2008100233A4
- Authority
- AU
- Australia
- Prior art keywords
- gel
- anaesthetic
- oral
- lignocaine
- flavouring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
13-03-08;15:36 ;A TatlocK Associates IP AUST Canberra ;61 3 9864 9900 7/ 16 00 o 1
O
SORAL ANAESTHETIC GEL n Area of the Invention O This invention relates to the area of topical anaesthesia or desensitisation. In 00 particular it relates to a topical anaesthetic which is adapted to be used on C mucous membranes and can be usefully applied in the field of dentistry despite having other applications.
Background to the Invention Local anaesthetics have been used in creams and ointments for many years.
Usually however there is a problem with the penetration of the drug or chemical due to the physio-chemical properties of both the drug and the base in which it is used.
In addition one of the products used topically on non mucous membranes is a cream and is not suitable for use on mucous membranes such as in the mouth.
Another product which can be used orally is a paste that has been formulated for the mouth but unfortunately does not adhere to the gum or mouth particularly well when used for dental purposes.
COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13 13-03-08;15:36 ;A Tatlock Associates IP AUST Canberra ;61 3 9664 9900 8/ 16 00 o 2 0 N It has been suggested that a gel base could be used to adhere in the mouth i however to date none exist which are able to provide the anaesthetic effect en required and additionally are quite unpalatable and therefore unsuitable for oral anaesthetic use.
Cci Outline of the Invention 00 It is an object of this invention to provide a topical anaesthetic for use on mucosal o surfaces which does not exhibit the problems outlined above. It is a further object of the invention to provide such a topical anaestheticwhich is sufficiently palatable that it can readily be used for dental purposes.
The invention is an oral anaesthetic gel including an anaesthetic in a transdermal gel base having added flavouring with a bitterness suppressant.
It is preferred that the gel base used be Pluronic Lecithin Organogel (PLO or Pluronic Gel) and that its viscosity be adjusted as required by the addition of suitable thickeners. It is further preferred that PLO strengths range from 2% to It is further preferred that the active agent or ingredient otherwise referred to as the active pharmaceutical ingredient (API) be lignocaine base US P or alternatively the HCL salt. It is also preferred that other active ingredients may be tetracaine benzocaine, amethocaine or prilocaine as salts.
COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13 13-03-08:15:36 ;A Tatlock Associates IR AUST Canberra ;61 3 9664 9900 9/ 16 00 3
O
CI In order that the invention may be more readily understood we shall describe by Sway of non limiting example a particular embodiment of the invention.
Examples of Embodiments of the Invention 8 A first preferred application of the invention is in the area of dentistry and will be 00 described here.
This embodiment of the invention is a gel formulation that is very quickly absorbed into the mucosa. As absorption is rapid the dentist can inject anaesthetic into a patient's gum with a major reduction in pain in the injection site in as little as seconds or up to 2 minutes.
Trauma is further reduced psychologically by the presence of palatable flavouring in the gel which masks the customary bitter taste of the analgesic material used as the anaesthetic.
Examples of the invention to be described here are PLO gel formulations having Lignocaine and being flavoured.
Dental Anaesthetic Gel A preferred formulation for a dental anaesthetic gel is as follows: Lignocaine USP 10.0g Sodium Metabisulphite 0.1g COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13 13-03-08;15:36 ;A Tatlock Associates IP AUST Canberra ;61 3 9554 9GOO 10/ 16 00 o4 0 CN Ethoxydiglycol Reageant Lecithin Isopropyl Palmitate/Myristate Solution 22ml eC Flavouring 12ml en Saccharin Sodium 0.20g O Stevia powder extract 1g 00 Simethicone 0.02ml o Pluronic Gel 20% up to 100ml.
The procedure for making the formulation is as follows: Calibrate a beaker to final volume Weigh the powder ingredients Add Lignocaine, Saccharine, Sodium Metabisulphate to the beaker with flavouring and ethoxy diglycol reagent.
Add a magnetic stirring bar and stir mixture well Create a vortex with the stir bar and slowly add the stevia to avoid lumps.
Add lecithin isopropyl myristate solution and allow lignocaine to dissolve remove stirring bar and add Pluronic gel 20% to volume pour mixture into an appropriately sized unguatorjar, remove excess Close lid tightly with mixing blade in place, expel all air and mix for a few minutes COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13 13-03--0;15:36 ;A Tatlock Assocates IP AUST Canbe-ra ;61 3 9864 9900 11/ 16 00 CIf desired the gel may be stored in a syringe with any excess air removed or Sotherwise stored as desired. The air removal is preferably achieved by turning the csyringe upside down and allowing the gel to settle on the plunger before removing the air.
O The compounding procedure is an important part of the process as force used in 00 mixing can encourage micelle formation. It is therefore preferred that this be reduced by using syringe to syringe techniques, a Dremel tool with mixing blade, electric mortars and ointment mills which can aid in the process.
Teething Gel A preferred formulation for a teething gel is as follows: Lignocaine USP Chlorhexadine Acetate 5% Solution 0.7ml Phenylepherine HCL USP 0.25g Sodium Metabisulphate 0.1g Ethoxy Diglycol Reagent Lecithin Isopropyl Palmitate/Myristate Solution 22ml Flavouring 12ml Pluronic Gel 20% up to 100ml.
The procedure for making the formulation is as follows: COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13 13-03-08;15:36 ;A Tatlock Associates IP AUST Canberra ;61 3 9664 9900 #12/ 16 00 O 6 0 C Weigh the Lignocaine, Phenylepherine HCI, Sodium Metabisulphate i and add to an appropriately calibrated beaker.
n Measue the Ethoxy Diglycol Reagent, and Lecithin Isopropyl Palmitate Solution, Chlorhexidine solution and add to the beaker en with a magnetic stirring bar.
O place beaker on a stirring plate and stir until the ingredients are 00 mixed o- whilst stirring add flavouring, sweetener, bitterness suppressant and colour if necessary remove stirring bar and add Pluronic gel 20% to volume pour mixture into an appropriately sized unguatorjar, remove excess Close lid tightly with mixing blade in place, expel all air and mix for a few minutes If desired the gel may be stored in a syringe with any excess air removed or otherwise stored as desired. The air removal is preferably achieved by turning the syringe upside down and allowing the gel to settle on the plunger before removing the air.
The compounding procedure is an important part of the process as force used in mixing can encourage micelle formation. It is therefore preferred that this be reduced by using syringe to syringe techniques, a Dremel tool with mixing blade, electric mortars and ointment mills which can aid in the process.
COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13 13--03-08;15:35 ;A Tatlock Associates P AUST Canberra ;61 3 9664 9900 13/ 18 00 7 c While a variety of flavours may be used they may include the following: SPINA COLADA per 100ml Bitterness Suppressant 2.5ml, Pineapple 3ml, Pina Colada 2.5ml, Peach Oil Coconut 1 ml, yellow 0.2ml O CARAMEL per 100 ml 00 Bitterness Suppressant 2.5ml, Cinnamon Oil 1ml, Caramel 8ml STRAWBERRY per 100 ml Bitterness suppressant 2.5ml, Strawberry 4ml, Blackberry Oil 1ml, watermelon Krisgel to thicken, red 0.1ml ORANGE per 100 ml Bitterness suppressant 2.5ml, Orange cream 3.5ml, Orange natural concentrate Tangerine oil 1ml, red 0.1ml, yellow 0.1ml BUBBLEGUM per 100 ml drp sweet, 50 drp bitter, 70drp bubble, 60drp banana, 40 drp grape TROPICAL FLAVOUR per 100ml drp sweet, 50 drp bitter, 80 drp strawberry, 20 drp peach oil, 10 drppineapple, dro pina colada, 10 drp coconut, 10 drp banana COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13 13-03-08;15:36 ;A Tatlock Associates IP AUST Canberra ;61 3 9664 9900 14/ 16 00 o 8 Ci WILD BERRY per 100ml drp sweet, 50 drp bitter, 80 drp strawberry, 20 drp blackberry oil, 40 drp cn watermelon and 2% Krisgel to thicken.
en The above are examples of the gel formulation of the invention and it is envisaged o that actual concentrations of ingredients can vary as can the actual ingredients 00 which are chosen depending on the specific application.
0 For example the strength of the analgesic used in the gel for dentistry could be typically up to 10% lignocaine as described above while for over the counter type medications such as the teething gel 1% or 2% could be used.
In addition the previously suggested anaesthetic agents can generally be used up to 10% to achieve a specified effect while benzocaine can be up to As has also been suggested the viscosity of any batch of the gel formulation can be adjusted by adding an appropriate thickener.
Clearly the concept of can be achieved in a variety of ways and while particular embodiments of the invention have been described herein it is to be understood that variations and modifications in the features described can still lie within the scope of the invention.
COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13
Claims (1)
13-03-08:15:38 ;A TatlocK Associates IP AUST Canberra ;61 3 9664 9900 1/ 00 O 9 C The claims defining the invention are as follows: 1. An oral anaesthetic gel including an anaesthetic in a transdermal gel base m having added flavouring with a bitterness suppressant. en 2. An oral anaesthetic gel as claimed in claim 1 wherein the base is Pluronic o Gel in the range of 10% to 00 o 3. An oral anaesthetic gel as claimed in any one of claims 1 to 3 wherein the anaesthetic is Lignocaine in the range 1% to 4. An oral anaesthetic gel as claimed in claim 3 for use as a teething gel including Lignocaine USP 1 to 3g, Chlorhexidine Acetate 5% solution 0.3 ml to 1.0ml, Phenylephrine HCL USP 0.1g to 0.5gm, Sodium Metabisulphite 0.01gmto 0.2gm, Ethoxyl Diglycol Reagent 5ml, to 15ml Lecithin Isopropyl Palmate/Myristrate Solution, Flavouring 5ml to 20ml, Pluronic Gel 10% to to 100ml. An oral anaesthetic gel as claimed in claim 4 for use in dentistry including Lignocaine USP 5mg to 15mg, Sodium Metabisulphite 0.01gm to 0.2gm, Ethoxy Diglycol Reagent 5ml to 15ml, Lecithin Isopropyl Palmitate/Myristrate solution 15ml to 30ml, flavouring 5 to 20ml, Saccharin Sodium 0.1gm to 0.3gm, Stevia powder extract 0.1gm to 0.4gm, Simethicone 0.01 to0.05ml, and Pluronic Gel 10% to COMS ID No: ARCS-182858 Received by IP Australia: Time 16:39 Date 2008-03-13
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008100233A AU2008100233B4 (en) | 2004-01-15 | 2008-03-13 | Oral anaesthetic gel |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004900176 | 2004-01-15 | ||
AU2004313612A AU2004313612A1 (en) | 2004-01-15 | 2004-12-22 | Oral anaesthetic gel |
AU2008100233A AU2008100233B4 (en) | 2004-01-15 | 2008-03-13 | Oral anaesthetic gel |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2004313612A Division AU2004313612A1 (en) | 2004-01-15 | 2004-12-22 | Oral anaesthetic gel |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2008100233A4 true AU2008100233A4 (en) | 2008-04-17 |
AU2008100233B4 AU2008100233B4 (en) | 2008-11-20 |
Family
ID=39338474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2008100233A Ceased AU2008100233B4 (en) | 2004-01-15 | 2008-03-13 | Oral anaesthetic gel |
Country Status (1)
Country | Link |
---|---|
AU (1) | AU2008100233B4 (en) |
-
2008
- 2008-03-13 AU AU2008100233A patent/AU2008100233B4/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2008100233B4 (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000505093A (en) | Tasteful aqueous liquid compositions for bitter agents | |
EP1909798A2 (en) | Oral suspension of prednisolone acetate | |
JP2012505172A (en) | Liquid pharmaceutical formulation with paracetamol | |
BR112021008197A2 (en) | edaravone suspension for oral administration | |
WO2016028968A1 (en) | Natural suspending agent including a synergistic blend of xanthan gum and konjac powder for oral pharmaceutical suspensions | |
TW200808374A (en) | Sugar-free storage-stable antihistaminic syrups | |
US9326935B2 (en) | Atomoxetine solution | |
JP2012515154A (en) | Formulation for oral mucosal administration of analgesic molecule and / or antispasmodic molecule | |
MX2010011701A (en) | Liquid formulation for deferiprone with palatable taste. | |
US20070110689A1 (en) | Oral anaesthetic gel | |
EP1143973A2 (en) | Compositions having improved stability | |
EP1146876A2 (en) | Compositions having improved stability | |
AU2008100233A4 (en) | Oral anaesthetic gel | |
CN111773203A (en) | Preparation process of phenylephrine hydrochloride-containing composition | |
EP3669879A1 (en) | Pharmaceutical composition in the form of an oral suspension including a flavonoid fraction comprising diosmin, and xanthan gum | |
ES2209490T3 (en) | ORAL SERTRALINE CONCENTRATE. | |
AU2004313612A1 (en) | Oral anaesthetic gel | |
JP2008531556A (en) | Aqueous liquid pharmaceutical composition stable at room temperature | |
AU2011203572A1 (en) | Oral anaesthetic gel | |
US11617795B2 (en) | Pharmaceutical syrup formulation or suspension | |
US20220387363A1 (en) | Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition | |
NL2024160B1 (en) | Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition | |
JPH05194232A (en) | Orally administering liquid agent of trimethoprim | |
WO2023203124A1 (en) | New formulation of atropine | |
GB2617419A (en) | Stable composition of chloral hydrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGI | Letters patent sealed or granted (innovation patent) | ||
FF | Certified innovation patent | ||
MK22 | Patent ceased section 143a(d), or expired - non payment of renewal fee or expiry |